This content is only available for ASCRS Members
This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
Purpose
To compare adverse events, refractive, and visual outcomes of Implantable Phakic Contact Lens (IPCL, Care Group, Gujarat, India) to Implantable Collamer Lenses (ICL, Staar Surgical, Lake Forest, CA, USA) for correction of high myopia and myopic astigmatism.
Methods
Observational consecutive case series. Inclusion criteria: myopic and myopic astigmatic eyes with implantation of spherical or toric monofocal IPCL V 2.0 or ICL V 4.0 for full correction in which high myopia and / or corneal conditions have excluded a laser-based refractive procedure. Exclusion criteria: Internal anterior chamber depth <2.8 mm, central endothelial cell count < 2000/cm2. One hundred-nineteen eyes were included (43 eyes IPCL).
Results
No adverse events except postoperative pressure spikes occurred within the first 3 months. At 3 months, mean spherical equivalent refraction was +0.06+/-0.38 D (range: -0.63 to +1.25 D) after IPCL implantation and +0.06+/-0.44 D (range: -1.13 to +1.88 D) after ICL implantation. Mean cylinder was -0.38 +/- 0.44 D (range: 0 to -2.75D) and -0.38+/-0.41 D (range: 0 to -1.75 D) with IPCL and ICL, respectively. Mean uncorrected distance visual acuity (UDVA) was 1.13 (decimal scale) and 1.04 with ICPL and ICL, respectively. Mean efficacy index was 1.13 and 1.04 with IPCL and ICL, respectively. Mean safety index was 1.28 and 0.89 with IPCL and ICL, respectively.
Conclusion
We found equally good visual and refractive outcomes with IPCL and ICL for the correction of high and moderate myopia with or without astigmatism. There is no need for nomogram adjustment when transitioning from ICL to IPCL. However, longer follow-up is warranted to determine stability of results and possible long-term adverse events.
To compare adverse events, refractive, and visual outcomes of Implantable Phakic Contact Lens (IPCL, Care Group, Gujarat, India) to Implantable Collamer Lenses (ICL, Staar Surgical, Lake Forest, CA, USA) for correction of high myopia and myopic astigmatism.
Methods
Observational consecutive case series. Inclusion criteria: myopic and myopic astigmatic eyes with implantation of spherical or toric monofocal IPCL V 2.0 or ICL V 4.0 for full correction in which high myopia and / or corneal conditions have excluded a laser-based refractive procedure. Exclusion criteria: Internal anterior chamber depth <2.8 mm, central endothelial cell count < 2000/cm2. One hundred-nineteen eyes were included (43 eyes IPCL).
Results
No adverse events except postoperative pressure spikes occurred within the first 3 months. At 3 months, mean spherical equivalent refraction was +0.06+/-0.38 D (range: -0.63 to +1.25 D) after IPCL implantation and +0.06+/-0.44 D (range: -1.13 to +1.88 D) after ICL implantation. Mean cylinder was -0.38 +/- 0.44 D (range: 0 to -2.75D) and -0.38+/-0.41 D (range: 0 to -1.75 D) with IPCL and ICL, respectively. Mean uncorrected distance visual acuity (UDVA) was 1.13 (decimal scale) and 1.04 with ICPL and ICL, respectively. Mean efficacy index was 1.13 and 1.04 with IPCL and ICL, respectively. Mean safety index was 1.28 and 0.89 with IPCL and ICL, respectively.
Conclusion
We found equally good visual and refractive outcomes with IPCL and ICL for the correction of high and moderate myopia with or without astigmatism. There is no need for nomogram adjustment when transitioning from ICL to IPCL. However, longer follow-up is warranted to determine stability of results and possible long-term adverse events.
View More Presentations from this Session
This presentation is from the session "SPS-104 Refractive Procedure Outcomes: SMILE, SMILE & CXL, ICL" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.